The detection of microglial EVs in the plasma and measurement of their RNA cargoes show promise as potential non-invasive biomarkers to complement emerging biomarkers such as amyloid-beta and tau protein in diagnosing pre-symptomatic AD as well as other diseases in which neuroinflammation plays a role. Here, MAPT is linked to Alzheimer disease.